zurück

Vutrisiran (hereditary transthyretin-mediated amyloidosis with polyneuropathy (stage 1 or 2))

 

Subject:

  • Active Substance: Vutrisiran
  • Name: Amvuttra®
  • Therapeutic area: Hereditary transthyretin-mediated amyloidosis
  • Pharmaceutical company: Alnylam Germany GmbH

 

Time table:

  • Start: 15.10.2022
  • Publication of assessment: 16.01.2023
  • End of public hearing: 06.02.2023
  • Final decision by G-BA: beginning of April 2023

 

Comparative therapy:

  • Tafamidis (only for hATTR-PN stadium 1) or patisiran